Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Top Cited Papers
- 29 March 2018
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 378 (13), 1189-1199
- https://doi.org/10.1056/NEJMoa1716863
Abstract
BACKGROUND Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical value for the prediction of relapse has yet to be established. METHODS We conducted a study involving patients 18 to 65 years of age who had newly diagnosed AML. Targeted next-generation sequencing was carried out at diagnosis and after induction therapy (during complete remission). End points were 4-year rates of relapse, relapse-free survival, and overall survival. RESULTS At least one mutation was detected in 430 out of 482 patients (89.2%). Mutations persisted in 51.4% of those patients during complete remission and were present at various allele frequencies (range, 0.02 to 47%). The detection of persistent DTA mutations (i.e., mutations in DNMT3A, TET2, and ASXL1), which are often present in persons with age-related clonal hematopoiesis, was not correlated with an increased relapse rate. After the exclusion of persistent DTA mutations, the detection of molecular minimal residual disease was associated with a significantly higher relapse rate than no detection (55.4% vs. 31.9%; hazard ratio, 2.14; P<0.001), as well as with lower rates of relapse-free survival (36.6% vs. 58.1%; hazard ratio for relapse or death, 1.92; P<0.001) and overall survival (41.9% vs. 66.1%; hazard ratio for death, 2.06; P<0.001). Multivariate analysis confirmed that the persistence of non-DTA mutations during complete remission conferred significant independent prognostic value with respect to the rates of relapse (hazard ratio, 1.89; P<0.001), relapse-free survival (hazard ratio for relapse or death, 1.64; P = 0.001), and overall survival (hazard ratio for death, 1.64; P = 0.003). A comparison of sequencing with flow cytometry for the detection of residual disease showed that sequencing had significant additive prognostic value. CONCLUSIONS Among patients with AML, the detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse and survival rates, but the detection of persistent mutations that are associated with clonal hematopoiesis did not have such prognostic value within a 4-year time frame. (Funded by the Queen Wilhelmina Fund Foundation of the Dutch Cancer Society and others.)Funding Information
- ZonMw (846002002)
- KWF Kankerbestrijding (EMCR 2015-7525)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (019.153LW.038)
This publication has 30 references indexed in Scilit:
- DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaLeukemia, 2017
- Measurable residual disease testing in acute myeloid leukaemiaLeukemia, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2016
- Assessment of Minimal Residual Disease in Standard-Risk AMLThe New England Journal of Medicine, 2016
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 2015
- Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future PerspectivesCurrent Hematologic Malignancy Reports, 2015
- Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Blood, 2014
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study GroupJournal of Clinical Oncology, 2011